NCT01300533View on ClinicalTrials.gov

A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

February 29, 2016

Conditions
Metastatic CancerCancerSolid Tumors
Interventions
DRUG

BIND-014

Trial Locations (6)

33905

Investigational Site #06, Fort Meyers

37203

Investigational Site #05, Nashville

48201

Investigational Site #03, Detriot

85258

Investigational Site #01, Scottsdale

90048

Investigational Site #04, Los Angeles

94904

Investigational Site #02, Greenbrae

Sponsors

Lead Sponsor

BIND Therapeutics
All Listed Sponsors
lead

BIND Therapeutics

INDUSTRY

NCT01300533 - A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer | Biotech Hunter | Biotech Hunter